1. Home
  2. GBIO vs JYNT Comparison

GBIO vs JYNT Comparison

Compare GBIO & JYNT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GBIO
  • JYNT
  • Stock Information
  • Founded
  • GBIO 2016
  • JYNT 2010
  • Country
  • GBIO United States
  • JYNT United States
  • Employees
  • GBIO N/A
  • JYNT N/A
  • Industry
  • GBIO Biotechnology: Pharmaceutical Preparations
  • JYNT Multi-Sector Companies
  • Sector
  • GBIO Health Care
  • JYNT Miscellaneous
  • Exchange
  • GBIO Nasdaq
  • JYNT Nasdaq
  • Market Cap
  • GBIO 64.8M
  • JYNT 154.2M
  • IPO Year
  • GBIO 2020
  • JYNT 2014
  • Fundamental
  • Price
  • GBIO $0.88
  • JYNT $10.22
  • Analyst Decision
  • GBIO Strong Buy
  • JYNT Strong Buy
  • Analyst Count
  • GBIO 2
  • JYNT 2
  • Target Price
  • GBIO $6.50
  • JYNT $17.50
  • AVG Volume (30 Days)
  • GBIO 581.0K
  • JYNT 50.4K
  • Earning Date
  • GBIO 03-05-2025
  • JYNT 03-06-2025
  • Dividend Yield
  • GBIO N/A
  • JYNT N/A
  • EPS Growth
  • GBIO N/A
  • JYNT N/A
  • EPS
  • GBIO N/A
  • JYNT N/A
  • Revenue
  • GBIO $18,582,000.00
  • JYNT $120,795,620.00
  • Revenue This Year
  • GBIO $212.74
  • JYNT $3.28
  • Revenue Next Year
  • GBIO N/A
  • JYNT N/A
  • P/E Ratio
  • GBIO N/A
  • JYNT N/A
  • Revenue Growth
  • GBIO 514.08
  • JYNT 5.26
  • 52 Week Low
  • GBIO $0.75
  • JYNT $8.94
  • 52 Week High
  • GBIO $4.65
  • JYNT $17.82
  • Technical
  • Relative Strength Index (RSI)
  • GBIO 28.66
  • JYNT 42.53
  • Support Level
  • GBIO $0.85
  • JYNT $9.98
  • Resistance Level
  • GBIO $1.01
  • JYNT $10.81
  • Average True Range (ATR)
  • GBIO 0.12
  • JYNT 0.43
  • MACD
  • GBIO 0.00
  • JYNT 0.02
  • Stochastic Oscillator
  • GBIO 7.50
  • JYNT 50.00

About GBIO Generation Bio Co.

Generation Bio Co is a genetics medicine company that is focused on creating gene therapies to provide durable and redosable treatments for patients suffering from rare and untreated diseases. The company focuses on liver and retina-related diseases. It is developing two distinct and complementary platforms that It believes will enable highly differentiated therapeutic applications. Its first platform is a potent, highly selective ctLNP delivery system for nucleic acids, which is designed to avoid off-target clearance by the liver and spleen, enabling ctLNPs to persist in systemic circulation and allowing for highly selective and potent ligand-driven targeting to specific tissues and cell types. Its second platform is its novel iqDNA, which is an optimized variant of its ceDNA.

About JYNT The Joint Corp.

The Joint Corp develops, owns, operates, supports, and manages chiropractic clinics through direct ownership, management arrangements, franchising, and the sales of regional developer rights throughout the United States. The doctors of chiropractic develop personalized treatment plans to relieve patients' pain and deliver ongoing preventative care. The Company has two operating business segments; the Corporate Clinics segment is comprised of the operating activities of the company-owned or managed clinics, and The Franchise Operations segment is comprised of the operating activities of the franchise business unit. The company generates maximum revenue from the Corporate clinic's segment.

Share on Social Networks: